These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 1675609)

  • 21. Tolerance and cross-tolerance to the activating effects of 3,4-methylenedioxymethamphetamine and a 5-hydroxytryptamine1B agonist.
    Callaway CW; Geyer MA
    J Pharmacol Exp Ther; 1992 Oct; 263(1):318-26. PubMed ID: 1357158
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modulation by 5-HT1A receptors of the 5-HT2 receptor-mediated tachykinin-induced contraction of the rat trachea in vitro.
    Germonpré PR; Joos GF; Pauwels RA
    Br J Pharmacol; 1998 Apr; 123(8):1571-8. PubMed ID: 9605563
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serotonin release contributes to the locomotor stimulant effects of 3,4-methylenedioxymethamphetamine in rats.
    Callaway CW; Wing LL; Geyer MA
    J Pharmacol Exp Ther; 1990 Aug; 254(2):456-64. PubMed ID: 1974635
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The 5-HT2 receptor antagonist, MDL 28,133A, disrupts the serotonergic-dopaminergic interaction mediating the neurochemical effects of 3,4-methylenedioxymethamphetamine.
    Schmidt CJ; Black CK; Taylor VL; Fadayel GM; Humphreys TM; Nieduzak TR; Sorensen SM
    Eur J Pharmacol; 1992 Sep; 220(2-3):151-9. PubMed ID: 1425989
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites.
    Battaglia G; Yeh SY; O'Hearn E; Molliver ME; Kuhar MJ; De Souza EB
    J Pharmacol Exp Ther; 1987 Sep; 242(3):911-6. PubMed ID: 2443644
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Further studies on N-methyl-1(3,4-methylenedioxyphenyl)-2-aminopropane as a discriminative stimulus: antagonism by 5-hydroxytryptamine3 antagonists.
    Glennon RA; Higgs R; Young R; Issa H
    Pharmacol Biochem Behav; 1992 Dec; 43(4):1099-106. PubMed ID: 1361990
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of 3,4-methylenedioxymethamphetamine on 3,4-dihydroxyphenylalanine accumulation in the striatum and nucleus accumbens.
    Nash JF; Meltzer HY; Gudelsky GA
    J Neurochem; 1990 Mar; 54(3):1062-7. PubMed ID: 1689375
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of the selective 5-HT2A receptor antagonist MDL 100,907 on MDMA-induced locomotor stimulation in rats.
    Kehne JH; Ketteler HJ; McCloskey TC; Sullivan CK; Dudley MW; Schmidt CJ
    Neuropsychopharmacology; 1996 Aug; 15(2):116-24. PubMed ID: 8840347
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Induction of spontaneous tail-flicks in rats by blockade of transmission at N-methyl-D-aspartate receptors: roles of multiple monoaminergic receptors in relation to the actions of antipsychotic agents.
    Millan MJ; Gobert A; Bervoets K; Rivet JM; Veiga S; Brocco M
    J Pharmacol Exp Ther; 2000 Feb; 292(2):672-83. PubMed ID: 10640305
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serotonin1B receptor activation mimics behavioral effects of presynaptic serotonin release.
    Rempel NL; Callaway CW; Geyer MA
    Neuropsychopharmacology; 1993 May; 8(3):201-11. PubMed ID: 8099482
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacological studies of the acute and chronic effects of (+)-3, 4-methylenedioxymethamphetamine on locomotor activity: role of 5-hydroxytryptamine(1A) and 5-hydroxytryptamine(1B/1D) receptors.
    McCreary AC; Bankson MG; Cunningham KA
    J Pharmacol Exp Ther; 1999 Sep; 290(3):965-73. PubMed ID: 10454466
    [TBL] [Abstract][Full Text] [Related]  

  • 32. (1-(2,5-dimethoxy-4 iodophenyl)-2-aminopropane)-induced head-twitches in the rat are mediated by 5-hydroxytryptamine (5-HT) 2A receptors: modulation by novel 5-HT2A/2C antagonists, D1 antagonists and 5-HT1A agonists.
    Schreiber R; Brocco M; Audinot V; Gobert A; Veiga S; Millan MJ
    J Pharmacol Exp Ther; 1995 Apr; 273(1):101-12. PubMed ID: 7714755
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antagonist properties of LY 165,163 at pre- and postsynaptic dopamine D2, D3 and D1 receptors: modulation of agonist actions at 5-HT1A receptors in vivo.
    Millan MJ; Rivet JM; Audinot V; Gobert A; Lejeune F; Brocco M; Newman-Tancredi A; Maurel-Remy S; Bervoets K
    J Pharmacol Exp Ther; 1995 Jun; 273(3):1418-27. PubMed ID: 7791116
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interactions of methylenedioxymethamphetamine with monoamine transmitter release mechanisms in rat brain slices.
    Fitzgerald JL; Reid JJ
    Naunyn Schmiedebergs Arch Pharmacol; 1993 Mar; 347(3):313-23. PubMed ID: 8097569
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neuroanatomic specificity and time course of alterations in rat brain serotonergic pathways induced by MDMA (3,4-methylenedioxymethamphetamine): assessment using quantitative autoradiography.
    Battaglia G; Sharkey J; Kuhar MJ; de Souza EB
    Synapse; 1991 Aug; 8(4):249-60. PubMed ID: 1681594
    [TBL] [Abstract][Full Text] [Related]  

  • 36. S 14671: a novel naphthylpiperazine 5-HT1A agonist of high efficacy and exceptional in vivo potency.
    Millan MJ; Canton H; Rivet JM; Lejeune F; Laubie M; Lavielle G
    Eur J Pharmacol; 1991 Oct; 203(2):319-22. PubMed ID: 1839284
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antagonists at the NMDA recognition site and blockers of the associated ion channel induce spontaneous tail-flicks in the rat.
    Millan MJ
    Eur J Pharmacol; 1991 Oct; 203(2):315-8. PubMed ID: 1724759
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 3,4-Methylenedioxyamphetamine (MDA) analogues exhibit differential effects on synaptosomal release of 3H-dopamine and 3H-5-hydroxytryptamine.
    McKenna DJ; Guan XM; Shulgin AT
    Pharmacol Biochem Behav; 1991 Mar; 38(3):505-12. PubMed ID: 1829838
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of 5-hydroxytryptamine3 receptor agonists on phosphoinositides hydrolysis in the rat fronto-cingulate and entorhinal cortices.
    Edwards E; Harkins K; Ashby CR; Wang RY
    J Pharmacol Exp Ther; 1991 Mar; 256(3):1025-32. PubMed ID: 1848625
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serotonin antagonists fail to alter MDMA self-administration in rats.
    Schenk S; Foote J; Aronsen D; Bukholt N; Highgate Q; Van de Wetering R; Webster J
    Pharmacol Biochem Behav; 2016 Sep; 148():38-45. PubMed ID: 27264435
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.